Your browser is no longer supported. Please, upgrade your browser.
JAGX Jaguar Health, Inc. monthly Stock Chart
Jaguar Health, Inc.
Index- P/E- EPS (ttm)-0.67 Insider Own2.14% Shs Outstand103.76M Perf Week-22.32%
Market Cap21.20M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float58.58M Perf Month47.62%
Income-5.40M PEG- EPS next Q- Inst Own11.10% Short Float8.57% Perf Quarter57.15%
Sales2.80M P/S7.57 EPS this Y50.20% Inst Trans-26.23% Short Ratio0.48 Perf Half Y-51.01%
Book/sh0.57 P/B0.36 EPS next Y- ROA-30.20% Target Price1.25 Perf Year-79.77%
Cash/sh0.00 P/C105.99 EPS next 5Y40.00% ROE-128.70% 52W Range0.10 - 1.30 Perf YTD46.10%
Dividend- P/FCF- EPS past 5Y- ROI-978.10% 52W High-84.28% Beta-
Dividend %- Quick Ratio0.20 Sales past 5Y- Gross Margin90.80% 52W Low94.57% ATR0.04
Employees17 Current Ratio0.30 Sales Q/Q2084.80% Oper. Margin- RSI (14)53.32 Volatility14.58% 22.25%
OptionableNo Debt/Eq0.51 EPS Q/Q123.40% Profit Margin- Rel Volume0.56 Prev Close0.21
ShortableYes LT Debt/Eq0.35 Earnings- Payout- Avg Volume10.43M Price0.20
Recom2.00 SMA2015.39% SMA5031.36% SMA200-35.35% Volume5,890,924 Change-4.26%
Jul-11-17Initiated Rodman & Renshaw Buy $2
Mar-13-18 07:02PM  Why Jaguar Health Incs (NASDAQ:JAGX) CEO Pay Matters To You Simply Wall St. -9.32%
03:00PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Jaguar Health, Inc. Business Wire
08:05AM  Jaguar Health, Pipeline Review, Analyst Ratings, Milestones ACCESSWIRE
Mar-09-18 08:10AM  Todays Research Reports on Stocks to Watch: Atossa Genetics and Jaguar Health ACCESSWIRE -31.05%
Mar-08-18 09:00AM  FDA Indicates that Jaguar's Reasonable Expectation of Effectiveness Technical Section is Complete for Use of Canalevia for Treatment of Chemotherapy-Induced Diarrhea in Dogs ACCESSWIRE +131.00%
Mar-05-18 08:10AM  Report: Developing Opportunities within TripAdvisor, Glu Mobile, KeyCorp, SMART SAND INC, Jaguar Animal Health, and Cleveland-Cliffs Future Expectations, Projections Moving into 2018 GlobeNewswire
Mar-02-18 09:00AM  Jaguar Health Subsidiary, Napo Pharmaceuticals, Signs Agreement with Pharmacy Services Provider "Transition Patient Services" to Establish Nationwide Pilot "Mytesi Direct" Program ACCESSWIRE
Mar-01-18 01:23PM  How Financially Strong Is Jaguar Health Inc (NASDAQ:JAGX)? Simply Wall St.
Jan-22-18 04:00PM  Jaguar Health Provides Updates Regarding Commercial, Educational & Product Development Programs and 2017 Results for Mytesi Since Merger (AugustDecember 2017) Business Wire
Jan-18-18 09:00AM  Jaguar Health to Host Conference Call Monday, January 22nd at 4:15 p.m. Eastern Time to Provide Updates Regarding Jaguar and Napo Pharmaceuticals Commercial, Educational & Product Development Activities and 2017 Results Business Wire +21.13%
08:30AM  Napo Pharmaceuticals Comments on the Passing of HIV/AIDS Activist and Research Pioneer Dr. Mathilde Krim Business Wire
Jan-06-18 11:50AM  Jaguar Health Inc (NASDAQ:JAGX): Has Recent Earnings Growth Beaten Long-Term Trend? Simply Wall St.
Jan-01-18 09:19AM  Jaguar Health, Inc. :JAGX-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018 Capital Cube
Dec-26-17 11:00AM  WallStreet Research(TM) Announces Release of Corporate Profile Coverage on Jaguar Health, Inc. (NASDAQ: JAGX) ACCESSWIRE
Dec-14-17 10:09AM  Jaguar Health and Dubai-based Seed Mena Enter Collaboration Agreement for Equilevia, Jaguars Personalized, Premium Product for Total Gut Health and Wellness in Horses Business Wire +5.52%
Dec-12-17 09:00AM  New Survey Finds People Living With HIV With Diarrhea Often Suffer in Silence Business Wire
Dec-01-17 04:10PM  Jaguar Health Announces Adjournment of Special Meeting of Stockholders Until Friday, December 15, 2017 Business Wire
09:00AM  Keep Your Pants On Campaign From Napo Pharmaceuticals Chosen as Best HIV-Related Awareness Campaign of 2017 by Healthline Business Wire
Nov-30-17 02:05PM  What You Must Know About Jaguar Health Incs (JAGX) Financial Strength Simply Wall St.
Nov-27-17 09:00AM  Jaguar Health Enters Share Purchase Agreement for 2 Million Shares and Common Stock Purchase Agreement Relating to a 10 Million Share Equity Line Offering With L2 Capital, LLC Business Wire
Nov-20-17 09:36AM  Jaguar Health Files First Quarterly Earnings Report Since July 2017 Merger with Napo Pharmaceuticals Business Wire
Nov-16-17 09:15AM  Jaguar Health Presenting Neonorm Calf at Western Organic Dairy Producers Alliance Conference Business Wire -5.38%
Nov-15-17 09:02AM  Dr. Roscoe M. Moore Jr., DVM, MPH, Ph.D., DSc Joins Napo Pharmaceuticals Scientific Advisory Board for HIV for Mytesi, Napos FDA-Approved Human Prescription Drug Business Wire -6.88%
Nov-14-17 05:54PM  Year-to-Date Gross Sales for Mytesi, the FDA-Approved Human Prescription Drug Product of Jaguar Healths Wholly-Owned Subsidiary, Napo Pharmaceuticals, Total $2.8 Million Business Wire
03:27PM  Todays Jaguar Health Conference Call Moved to 5:45 p.m. Eastern Time Business Wire
06:09AM  Is Jaguar Health Inc (JAGX) A Healthcare Industry Laggard Or Leader? Simply Wall St.
Nov-09-17 04:12PM  Jaguar Health to Host Earnings Conference Call Tuesday, November 14th at 4:30 p.m. Eastern Time Business Wire
Nov-08-17 07:30AM  Jaguar Health Enters Non-Binding Agreement of Terms to Issue a Secured Convertible Note to Iliad Research and Trading, L.P. (an Affiliate of Chicago Venture Partners, L.P.), as Jaguar Expands Commercial Efforts for Mytesi Business Wire +13.85%
Nov-07-17 09:00AM  Jaguar Health Receives Approval from The American Association of Veterinary State Boards RACE Committee for Continuing Education Program for Veterinarians and Veterinary Technicians on Diarrhea in Foals Business Wire -6.23%
Nov-01-17 09:00AM  Jaguar Health Subsidiary Napo Pharmaceuticals Launches New Website for Mytesi, Napos FDA-Approved, First-in-Class Anti-Secretory Human Prescription Drug Business Wire
08:00AM  Investor Expectations to Drive Momentum within VWR, The Michaels Companies, KalVista Pharmaceuticals, PACCAR, Jaguar Health, and CPI Card Group Discovering Underlying Factors of Influence GlobeNewswire
Oct-26-17 09:00AM  Jaguar Health Subsidiary Napo Pharmaceuticals Launches National Keep Your Pants On Unless You Dont Want To Campaign to Highlight the Need to Recognize and Treat Diarrhea in People Living With HIV/AIDS Business Wire
Oct-20-17 03:56PM  Why Jaguar Health Incs (JAGX) Ownership Structure Is Important Simply Wall St.
Oct-19-17 09:00AM  Jaguar Health Subsidiary Napo Pharmaceuticals Establishes Scientific Advisory Boards for Planned Follow-on Indications for Mytesi, Napos FDA-approved Human Prescription Drug Business Wire
Oct-18-17 09:04AM  Napo Pharmaceuticals Endorses Prevention Access Campaigns U=U Consensus Statement for People Living With HIV/AIDS (PLWHA) Business Wire
Oct-04-17 08:00AM  Jaguar Health, Product Pipeline Review and Outlook ACCESSWIRE -6.56%
Oct-02-17 08:00AM  Today's Research Reports on Trending Tickers: Synergy Pharmaceuticals and Jaguar Health ACCESSWIRE +19.25%
Sep-29-17 01:24PM  Jaguar Health Prices $4.25 Million Public Offering of Common Stock Business Wire -50.22%
Sep-28-17 09:13AM  Jaguar Subsidiary Napo Pharmaceuticals Files CMC Supplement with FDA for Sample-Size Bottles of Mytesi, Napos FDA-Approved Human Drug, to Support Upcoming National Sample Campaign Business Wire
Sep-25-17 09:00AM  Jaguar Subsidiary Napo Pharmaceuticals and Glenmark Pharmaceuticals Sign Agreement Returning Key Rights in 141 Countries to Napo, Solidifying Jaguars Global Commercial Control of Mytesi (Crofelemer), Jaguars FDA-Approved Human Drug Business Wire +18.74%
Sep-20-17 09:00AM  FDA Indicates That Jaguars Canalevia Drug Product Candidate Qualifies as Minor Use for Exercise-Induced Diarrhea (EID) in Dogs, Rendering Canalevia Eligible for Conditional Approval for This Indication Business Wire
Sep-18-17 10:07AM  Advocates Tez Anderson and Josh Robbins to Host Facebook Live Conversation on HIV/AIDS and Aging Awareness Day to Discuss Issues Affecting Long Term Survivors Business Wire
08:16AM  Jaguar Health Announces Proposed Public Offering of Common Stock Business Wire
Sep-15-17 09:00AM  Jaguar Health Subsidiary Napo Pharmaceuticals Expands Mytesi Salesforce With Hire of Experienced HIV & GI Drug Sales Reps in Key U.S. Markets Business Wire -16.60%
Sep-12-17 12:16PM  New Survey Ranks Diarrhea as Number One Gastrointestinal Complaint of HIV/AIDS Patients Business Wire +6.82%
Aug-25-17 10:48AM  Jaguar Health, Inc. :JAGX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 Capital Cube -18.37%
Aug-16-17 09:00AM  Jaguar Health Company Name Now Updated on Post-Merger Business Wire -7.80%
Aug-07-17 09:00AM  Jaguar Health Subsidiary Napo Pharmaceuticals Receives Orphan-Drug Designation for Mytesi (crofelemer) for Treatment of Short Bowel Syndrome Business Wire
Aug-04-17 05:00PM  Monteverde & Associates PC Files Class Action Lawsuit on Behalf of Shareholders of Jaguar Animal Health, Inc. in the Northern District of California PR Newswire +5.50%
Jul-31-17 07:33PM  The Merger of Jaguar Animal Health and Napo Pharmaceuticals is Effective Business Wire -21.68%
Jul-27-17 08:08PM  Stockholders of Jaguar Animal Health and Napo Pharmaceuticals Vote to Approve Merger Business Wire
Jul-24-17 09:00AM  New Data Shows Dramatic Reduction in Chronic Diarrhea Episodes with Crofelemer (Mytesi) Treatment Business Wire
Jul-18-17 09:00AM  Jaguar Neonorm Foal Study Accepted for Publication in Veterinary Journal Business Wire
Jul-06-17 05:38PM  Jaguar Animal Health to Hold Special Meeting of Stockholders July 27, 2017 to Vote Upon the Consummation of its Proposed Merger with Napo Pharmaceuticals, Inc. Business Wire
Jun-30-17 01:21PM  SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Jaguar Animal Health, Inc. - JAGX PR Newswire
Jun-27-17 09:00AM  Napo Pharmaceuticals to Present New Crofelemer (Mytesi) Data at International Aids Society Conference on HIV Science Business Wire
Jun-14-17 09:00AM  Jaguar Animal Healths Neonorm Calf Obtains OMRI Listing and Can Now be Used in Production of Certified Organic Dairy and Beef Cattle Business Wire
Jun-07-17 09:00AM  Jaguar Animal Health Launches Commercial Website for Neonorm Foal & Neonorm Calf Business Wire
Jun-05-17 09:00AM  Jaguar Animal Health and Napo Pharmaceuticals Announce Filing of Two Orphan Drug Designation Applications with FDA for Mytesi for Serious Unmet Medical Needs Business Wire
Jun-02-17 09:52AM  Jaguar Animal Health, Inc. :JAGX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
May-25-17 09:00AM  Lisa Conte, CEO of Jaguar Animal Health and Napo Pharmaceuticals, to Present at the Southern California Investment Forum May 31, 2017 in Los Angeles Business Wire
May-24-17 09:00AM  Napo Pharmaceuticals New Mytesi Video Calls Attention to the Continuing Widespread Problem of Diarrhea in People Living With HIV/AIDS Business Wire
May-10-17 09:03AM  Jaguar Animal Health and Napo Pharmaceuticals Appoint Dr. Pravin Chaturvedi to Chair Scientific Advisory Board Business Wire
Apr-28-17 09:00AM  Jaguar Signs Distribution Agreement for Japan for Neonorm Foal & Neonorm Calf Business Wire
Apr-06-17 09:00AM  Jaguar and Napo Issue Commercial Updates Business Wire
Apr-02-17 05:40PM  After Clearing Valeant Litigation, Jaguar and Napo Pharmaceuticals Reunite
Mar-31-17 11:17AM  Jaguar Animal Health Stock Rises on Napo Pharma Merger +5.26%
10:01AM  Jaguar Animal Health Stock Skyrocketing on Napo Pharma Merger
09:47AM  JAGUAR ANIMAL HEALTH, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equit
09:00AM  Jaguar Animal Health and Napo Pharmaceuticals Enter Definitive Merger Agreement Business Wire
Mar-28-17 09:00AM  Jaguar Enters Exclusive Evaluation Period With Multinational Animal Health Pharmaceutical Firm Regarding Equilevia, Jaguars Drug Product Candidate for Equine Gastric Ulcer Syndrome Business Wire
Mar-16-17 08:39AM  Jaguar Animal Health, Inc. :JAGX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017 Capital Cube
Mar-14-17 03:07PM  Jaguar Animal Health, Inc. :JAGX-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
09:08AM  Jaguar Animal Health Seeks MUMS Designation for Canalevia for Exercise-Induced Diarrhea in Dogs Business Wire
Mar-03-17 09:00AM  Jaguar Animal Health to Participate in 29th Annual ROTH Conference the Week of March 13th in Orange County, California Business Wire
Feb-24-17 04:49PM  JAGUAR ANIMAL HEALTH, INC. Files SEC form 8-K, Other Events +7.48%
Feb-22-17 01:04PM  JAGUAR ANIMAL HEALTH, INC. Financials
Feb-21-17 06:14AM  JAGUAR ANIMAL HEALTH, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +11.46%
Feb-15-17 03:12PM  JAGUAR ANIMAL HEALTH, INC. Files SEC form 10-K, Annual Report
Feb-14-17 09:00AM  Study Supporting Herd-wide Reduction in Incidence and Severity of Diarrhea With Prophylactic Use of Neonorm Calf Published in Journal of Dairy Science Business Wire
Feb-09-17 06:07AM  JAGUAR ANIMAL HEALTH, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, +51.40%
Feb-08-17 06:09PM  Jaguar Animal Health Enters Binding Agreement of Terms to Merge with Napo Pharmaceuticals Business Wire
Feb-02-17 09:00AM  Jaguar Animal Health Begins Entry Into Organic Market With Neonorm Calf Business Wire
Feb-01-17 09:30AM  Drug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on Arrowhead Pharmaceuticals and Jaguar Animal Health Accesswire -5.11%
Jan-31-17 03:20PM  JAGUAR ANIMAL HEALTH, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E +56.60%
05:05AM  Jaguar Animal Health, Elanco Announce Global Collaboration for Development, Co-Promotion of Canalevia; Jaguar to Receive Upfront Payment of $1.5M
05:00AM  Jaguar Animal Health, Elanco Enter Global Collaboration for Development, Co-Promotion of Canalevia Business Wire
Jan-10-17 04:21PM  Jaguar Animal Health, Inc. (NAS:JAGX) Given Company Update by Aegis Capital Corp. ABN Newswire
Jan-05-17 09:21AM  Jaguar Animal Health to Participate in Biotech Showcase 2017 Week of January 9th in San Francisco Business Wire
Jan-03-17 09:00AM  Napo Pharmaceuticals Secures $2 Million in Financing Business Wire -6.28%
Dec-30-16 05:04PM  JAGUAR ANIMAL HEALTH, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or +16.05%
Dec-19-16 05:26PM  JAGUAR ANIMAL HEALTH, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
09:00AM  Jaguar Animal Health Appoints Dr. Ari Azhir to Board of Directors Business Wire
Dec-15-16 04:36PM  JAGUAR ANIMAL HEALTH, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E -6.98%
Dec-12-16 09:04AM  Jaguar Animal Health and Henry Schein, Inc. Sign Exclusive Distribution Agreement for Neonorm Foal Business Wire +15.29%
Dec-09-16 09:00AM  Jaguar Animal Health Exhibits Neonorm Foal at American Association of Equine Practitioners Annual Convention Business Wire +28.79%
Dec-08-16 12:50PM  Jaguar Animal Health Gears Up for Secondary Offering -5.44%
Nov-29-16 04:32PM  JAGUAR ANIMAL HEALTH, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equit
Nov-23-16 09:00AM  Jaguar Animal Health Announces Private Placement of Common Stock and Warrants Business Wire
Nov-18-16 11:36AM  Jaguar Animal Health, Inc. :JAGX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016
Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing novel, sustainably derived gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Canalevia is the company's lead animal prescription drug product candidate intended for treatment of various forms of diarrhea in dogs; and Equilevia is Jaguar's non-prescription product for total gut health in equine athletes. Canalevia and Equilevia contain ingredients isolated and purified from the Croton lechleri tree, which is sustainably harvested. In addition, the Company's products include Neonorm Calf and Neonorm Foal. Mytesi, Canalevia, Equilevia, and Neonorm are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar Health, Inc. is based in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BOCHNOWSKI JAMES JDirectorJun 28Buy0.50100,00050,000797,935Aug 02 06:01 AM